首页> 美国卫生研究院文献>World Journal of Nephrology >Vascular response to vasodilator treatment in microalbuminuric diabetic kidney disease
【2h】

Vascular response to vasodilator treatment in microalbuminuric diabetic kidney disease

机译:微蛋白尿性糖尿病肾脏疾病对血管扩张药的血管反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Under common practice, the conventional diagnostic marker such as microalbuminuria determination does not recognized early stage of diabetic kidney disease (normoalbuminuria, chronic kidney disease stage 1, 2); due to the insensitiveness of the available marker. Treatment at later stage (microalbuminuria) simply slows the renal disease progression, but is rather difficult to restore the renal perfusion. Intrarenal hemodynamic study in these patients revealed an impaired renal perfusion and abnormally elevated renal arteriolar resistances. Treatment with vasodilators such as angiotensin converting enzyme inhibitor and angiotensin receptor blocker fails to correct the renal ischemia. Recent study on vascular homeostasis revealed a defective mechanism associated with an impaired nitric oxide production which would explain the therapeutic resistance to vasodilator treatment in microalbuminuric diabetic kidney disease. This study implies that the appropriate therapeutic strategy should be implemented at earlier stage before the appearance of microalbuminuria.
机译:在常规实践中,常规诊断标志物(如微量白蛋白尿的测定)不能识别出糖尿病肾脏疾病的早期阶段(正常白蛋白尿,慢性肾脏疾病的第1、2期);由于可用标记的不敏感性。后期的治疗(微量白蛋白尿)只会减慢肾脏疾病的进展,但恢复肾脏灌注却相当困难。这些患者的肾内血流动力学研究显示肾灌注受损和肾小动脉阻力异常升高。用血管扩张剂如血管紧张素转化酶抑制剂和血管紧张素受体阻滞剂治疗不能纠正肾脏缺血。最近对血管稳态的研究揭示了与一氧化氮产生受损有关的机制缺陷,这可以解释微蛋白尿糖尿病性肾脏疾病对血管扩张剂治疗的治疗抗性。这项研究表明,适当的治疗策略应在出现微量白蛋白尿之前的早期阶段实施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号